Skip links

Vyndaqel® (tafamidis meglumine)

Full Name Vyndaqel® (tafamidis meglumine)
Drug Vyndaqel
Manufacturer Pfizer
Route of Administration Oral
Site of Care Home
Approved Indication The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Disease Hereditary ATTR amyloidosis (hATTR) – Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM)
Therapeutic Area Cardiology
Enrollment Form Link Vyndaqel Enrollment Form
Phone Number 800-930-2043
Fax Number 877-684-3116
Product Website